Feitong (Chengdu) Biotech Co., Ltd. is a Chengdu Tianfu International Bio‑city–based company founded in 2017 focused on innovative antibody drug development for tumor immunotherapy and autoimmune diseases. The company was co-founded by Nobel Chemistry laureate and Stanford professor Roger Kornberg together with Dr. Li Qing. Its R&D platform emphasizes novel mechanisms, bispecific antibodies and highly differentiated monoclonal antibodies, and it has an international team with over two-thirds of staff holding PhDs or master’s degrees and five returning overseas experts. In 2021 the national drug review center accepted the clinical application for FTL001, a CD137 (4‑1BB)–targeting monoclonal antibody, and the company expected two Class I new drugs to enter clinical trials in 2022. The company completed a nearly RMB 100 million A round in December 2021 to accelerate multiple tumor immunotherapy pipelines into Phase I studies, support clinical registration submissions, and advance preclinical research on autoimmune candidates. 非同生物 is led by clinical immunology expert and serial entrepreneur Dr. Li Qing and brings together researchers and industry experts from top institutions. The company has rapidly built multiple core technology platforms, notably a site-specific PEGylation and an asymmetric bispecific antibody platform branded NanoPEGTM, which was described as at an "international advanced" level. 非同 is accelerating clinical registration submissions for its core products while other pipeline programs continue to progress steadily. Management emphasizes the team's complementary capabilities—scientists for discovery, industry experts for scale-up, and operators for ongoing business—derived in part from a Nobel-associated team landing domestically. The company recently completed a pre-A financing and is working with its investor on funding planning, product strategy, and post-investment support. No operating metrics (revenue/users) were disclosed in the article.

Total raised

$16M

Funding rounds

2

Latest round

Series A

Latest activity

Jan 2022